IMPLANTABLE DEVICE THERAPY FOR HEART FAILURE
|
|
- Jody Carmel Harrington
- 5 years ago
- Views:
Transcription
1 IMPLANTABLE DEVICE THERAPY FOR HEART FAILURE Nora Goldschlager, M.D. MACP, FACC, FAHA, FHRS Cardiology San Francisco General Hospital UCSF Disclosures: None LEADING CAUSES OF DEATH IN US Sudden cardiac death 375, Stroke 16, Lung cancer 9,1 Automobile accidents 5, Breast cancer 4,2 AIDS 16, American Heart Association 2 National Cancer Institute 21 National Transportation Safety Board 2 Center for Disease Control 21 NFPA, US Facts & Figures 2 emedicine Aug.22 Definition SUDDEN CARDIAC DEATH Death occurs within minutes Unwitnessed death Incidence 375, per year (approximately 43 every hour) 75, (2%) survive
2 UNDERLYING ARRHYTHMIA OF SUDDEN CARDIAC ARREST VT 62% Primary VF 8% Torsades de Pointes 13% Bradycardia 17% SUDDEN CARDIAC DEATH AND PROGRESSIVE HF Mortality in NYHA Class IV 3 to 7% 33% SCD, 56% HF NYHA Class III 2 to 5% 59% SCD, 26% HF NYHA Class II 5 to 15% 64% SCD, 12% HF PHARMACOLOGICAL THERAPY Classes of drugs evaluated for ability to prevent SCD in high-risk patients ACE inhibitors Beta blockers Class I antiarrhythmics d-sotalol Amiodarone Adapted from Bayés de Luna A. Am Heart J. 1989;117:
3 HIGH RISK GROUPS: DEPRESSED EJECTION FRACTION AND VENTRICULAR ECTOPY Survivorship Survival After Acute MI N EF VPD 536 3% <1/hr 113 3% 1/hr 8 <3% <1/hr 37 <3% 1/hr Bigger, JT. Am J Cardiol. 1986;57: Year 2 3 HIGH RISK GROUPS: DEPRESSED EJECTION FRACTION, VENTRICULAR ECTOPY 1 Survival No PVBs 1-1/h >1/h p =.2 p = Patients without LV dysfunction Risk of Sudden Death: Data from GISSI-2 Trial Maggioni AP Circ 1993;87: Days Patients Patients with with LV Dysfunction LV dysfunction CAST I ( ) CARDIAC ARRHYTHMIA SUPRESSION TRIAL Objective Test hypothesis that suppression of PVCs post-mi would reduce mortality Inclusion Post MI, > 1 PVCs per hour Patients 1,727 randomized to placebo vs active therapy with Encainide, Flecainide, or Moricizine Results After mean follow-up of 1 months, Encainide and Flecainide arms terminated prematurely due to excess death or cardiac arrest N Engl J Med 1989, 321:46-412
4 Survival CAST SURVIVAL CURVES Placebo (n-1371) Active Rx (n=138) p =.6 N Engl J Med 1989, 321: Months PRIMARY SUDDEN DEATH PREVENTION IN HEART FAILURE ACE Inhibitors Beta Blockers Amiodarone ACE INHIBITORS ACE inhibitors reduce mortality in LV dysfunction do they alter the risk of arrhythmic death? SOLVD and CONSENSUS trials no significant effect on SCD V-HeFT II mortality benefit attributable to decreased incidence of SCD Circulation 1998;97 N Engl J Med 1987;316(23): N Engl J Med 1991;325:33-31
5 Trials of Beta Blockers for Heart Failure: Effects on Sudden Cardiac Death CIBIS II 1999 MERIT-HF 1999 Meta- Analysis (17 Trials) Number 2,647 3,991 3,39 Lancet 1999;353:9-13 Lancet 1999;353:21-7 Circulation 1998;98: Drug Bisoprolol mg or Placebo Metoprolol mg or Placebo -- LVEF 35% 4% 23% Study Period (days) Mortality Risk Reduction All- Cause -34% P=.1-35% P=.6-31% Heart Failure % P=.1-32% Sudden Cardiac -44% P=.1-41% P=.2-16% CHF-STAT: CONGESTIVE HEART FAILURE SURVIVAL TRIAL OF ANTIARRHYTHMIC THERAPY Hypothesis: Amiodarone will reduce mortality in patients with HF and ventricular arrhythmias HF Class II, III, or IV EF 4% 1 PVCs/hour May be on ACE inhibitors, hydralazine, or nitrates Circulation 1996; Probability of survival CHF-STAT: ALL-CAUSE MORTALITY Ischemic Contr Clin Trials. 1992;13: Non-ischemic.4 Amiodarone.2 Placebo p =.61 p = Month Amiodarone Placebo
6 ICD CLINICAL TRIALS AVID CABG Patch CASH MADIT II CIDS DEFINITE MADIT DINAMIT MUSTT SCD-HEFT MADIT ( ) MULTICENTER AUTOMATIC DEFIBRILLATOR IMPLANTATION TRIAL Objective ICDs vs conventional medical Rx in high risk patients Inclusion MI 3+ weeks prior to study, asymptomatic non-sustained VT, EF <35%, NYHA Class I-III, and no indication for coronary revascularization Exclusion previous cardiac arrest, VT, CABG within past 2 months, PTCA in past 3 months, NYHA Class IV, or major noncardiac comorbidity N Engl J Med 1996;335: MADIT Patients 196 enrolled & randomized (95 ICD, 11 AARx therapy) Choice of conventional medical Rx left to the patient s attending Results ICDs reduced cardiac mortality by 57% in high risk patients relative to best conventional Rx MADIT was the first randomized ICD trial to show that the ICD save lives in the narrowly defined population of patients described in this study * N Engl J Med 1996;335: * Moss, Arthur J Cardiac Electrophysiology Review 1998; 2:6-7
7 % New Eng J Med 1996;335: MADIT: MORTALITY 15.8% 38.6% All-Cause Mortality ICD (95 pts) Conventional (11 pts) 11.6% 26.7% Cardiac Death ICD vs. Drugs:Reported Mortality Results Prospective Randomized Studies % Mortality % 15.8% 35.9% Drugs ICDs MADIT AVID CIDS CASH MADIT Study: 196 post MI patients, <.35 EF, inducible VT/VF despite procainamide; ICD vs. Drugs (74% Amiodarone); 2 year survival data. 2 AVID Study: 116 VT/VF patients; ICDs vs. Amiodarone/Sotalol; 3 year survival data. 3 CIDS Study: 659 VT/VF; ICDs vs. Amiodarone; 3 year survival data. 4 CASH Study: 346 VF patients; ICDs vs. Amiodarone/Metoprolol; 2 year survival data. 3.% 24.6% 25.% 19.6% 12.1% 1 4 CABG PATCH ( ) CORONARY ARTERY BYPASS GRAFT PATCH TRIAL Objective test ICD prophylaxis against sudden death Inclusion ischemic patients, with coronary heart disease, depressed EF, abnormal SAECG undergoing non-emergency coronary bypass graft surgery Exclusion Patients with prior history of sustained ventricular arrhythmia Patients 71,864 patients screened, 1422 eligible, 9 were randomized Results no significant mortality difference likely due to benefits of revascularization Bigger et al. N Engl J Med 1997;337:
8 CABG-PATCH: ALL-CAUSE MORTALITY Cumulative Mortality (%) ICD group 445 Control group Bigger et al. N Engl J Med 1997; 337: Defibrillator group Control group 24 Month MADIT II ( ) MULTICENTER AUTOMATIC DEFIBRILLATOR IMPLANTATION TRIAL II Objective evaluate ICD vs. medical therapy in patients with left ventricular dysfunction and MI Inclusion post MI patients with EF < 3%. No prior assessment of VT in EP lab Exclusion approved indication for an ICD; Coronary revascularization within 3 months; MI within the past 1 month Ann Noninvasive Electrocardiol 1999;4:83-1 MADIT II Patients 1,232 randomized in a 3:2 ratio to receive an ICD (752) or conventional medical therapy (49) Results over a 4-yr period with average follow-up of 2 months, ICD group resulted in a 5.6% absolute and 31% relative risk reduction in mortality over conventional group (14.2% vs. 19.8%) respectively Study terminated early due to this favorable result Ann Noninvasive Electrocardiol 1999;4:83-1
9 Probability of survival No. at risk Defibrillator Conventional MADIT II Conventional Moss, A. et. al. N Engl J Med 22; Year Defibrillator Mortality (%) MADIT II: Comparison with Other Landmark Trials JAMA 1982, 247: N Engl J Med 1984, 31: Pfeffer, et al. N Engl J Med 1992, 327: Moss, et al. N Engl J Med 22, 346: P < BHAT 1 n = 3837 HR =.74 Conv Rx Test Rx P = NS CASS 2 n = 78 HR =.89 P = P = SAVE 3 n = 2231 HR = MADIT II 4 n = 1232 HR =.69 MADIT II: Time from MI and ICD Benefit
10 DEFINITE ( ) DEFibrillator IN NON-ISCHEMIC CARDIOMYOPATHY TREATMENT EVALUATION Objective determine effectiveness of ICD in preventing death due to VT/VF in at-risk patients Inclusion non-ischemic cardiomyopathy, EF < 35%, symptomatic CHF, and NSVT or > 1 PVCs per hour Exclusion patients with no previous resuscitation from SCD or who have not yet experienced sustained ventricular arrhythmias CenterWatch Clinical Trials Listing Service Clinical Trial #12395 DEFINITE Patients 458 patients ICD vs drug therapy, all receive standard drug therapy for heart failure and beta blockers if tolerated Results 13.8 overall mortality in control vs 8.1% in ICD; RR cardiac arrest.26 in ICD arm CenterWatch Clinical Trials Listing Service Clinical Trial #12395 SCD-HeFT ( ) SUDDEN CARDIAC DEATH-HEART FAILURE Objective compare all-cause mortality between ICDs, amiodarone, and placebo in patients without clinically evident arrhythmias who are being treated for Class II or III HF Inclusion NYHA Class II or III CHF for > 3 months, and EF < 35% with no record of sustained ventricular arrhythmias Exclusion asymptomatic patients with EF > 35%, history of cardiac arrest or patients requiring AARx Patients 2,521 patients randomized to ICDs (shock only), amiodarone, or placebo Results at 2.5 years, ICD decreased mortality by 23%. Amiodarone did not improve survival
11 MORTALITY BY INTENTION-TO-TREAT Mortality Placebo vs: HR 97.5% CI P-Value Amio , ICD.77.86,.96.7 Months of follow-up Amiodarone ICD therapy Placebo ISSUES IN ICD Rx FOR 1º SCD PREVENTION Only 5-7% absolute mortality over 2-4yrs Only about 2% receive shocks in 3-5 yrs (2x the mortality in controls); only 1% of 1º prevention patients receive Rx 9% of patients exposed to Risk of infection Psychological Inappropriate trauma shocks Post-shock PEA? Proarrhythmia Most life-saving shocks occur in low-risk groups, in whom overall mortality is < 1% From Tung, Swerdlow. Circulation 29;12
12
13 CARDIAC RESYNCHRONIZATION THERAPY (CRT) EFFECTS OF RV APICAL PACING (VENTRICULAR DYSSYNCHRONY DUE TO FUNCTIONAL LBBB) Ventricular remodeling, wall motion abnormalities ischemia scores, reflecting alterations in blood flow or depolarization sequences LVEDD, LVESD, LA size LV fractional shortening MR AF CHF DUAL CHAMBER AND VVI ICD (DAVID) TRIAL Inclusion criteria: Pts requiring ICD but without bradycardia requiring pacing Endpoint: Death or hospitalization for CHF Pts: N = 56, 83% men, avg EF 27% Study stopped prematurely at FU 8.4 mos 4 2 New or worse CHF 4.2% Hazard ratio: % DDDR VVI 7 bpm 4 bpm (No pacing) JAMA 22;288:3155
14 DUAL CHAMBER AND VVI ICD (DAVID) TRIAL % 84% Survival free of composite endpoint one year 1% 6.5% 22% 13% Death JAMA 22;288:3155 DDDR VVI 7 bpm 4 bpm CHF hospitalization Implication: RV (apical) pacing may be detrimental in ICD pts with poor LV function g g g g MOST SUBSTUDY: % RV PACING CORRELATES WITH ADVERSE ENDPOINTS Risk of hospitalization for HF in DDDR group Increases exponentially as RV pacing increases from to 4% 2.6 x in HF hospitalizations if RVP >4% (vs RVP < 4%) Levels off at RV pacing between 4-1% Average HF hospitalization risk = 1% over a 33 month follow up Lowest risk of HF hospitalization = 2% in DDDR group paced <1% of the time Risk of AF =1% with each 1% increase in V pacing (VVIR or DDDR) Circulation 23;17:2932 % RV PACING AND OUTCOME: DAVID* TRIAL % primary endpoint: death or hospitalization for HF 1-yr survival free of endpoint: 84% VVI 4 vs 73% DDDR Months * ICD pts s brady indication Heart Rhythm 25;2:83 DDDR > 4% N = 126 VVI unpaced N = 195 DDDR 4% N = 58 p =.3 p =.7
15 RV PACING IN ICD PATIENTS: PROBABILITY OF CHF HOSPITALIZATION OR DEATH MADIT II Trend toward CHF JCE 25;16:359.4 MADIT II substudy % % RV pacing.2 relating to CHF, death, ICD shocks Most pts either paced <1% or >9% of time Unadjusted p <.1 VP 5% N = 198 N = 368 VP < 5% Years RV PACING AND VENTRICULAR ARRHYTHMIAS: PROBABILITY OF APPROPRIATE ICD Rx.4.2 Unadjusted p <.1 VP 5% VP < 5% Years MADIT substudy JCE 25;16:359 CARDIAC RESYNCHRONIZATION THERAPY: WEIGHT OF EVIDENCE More than 4 patients evaluated in randomized controlled trials Consistent improvement in quality of life, functional status, and exercise capacity Strong evidence for reverse remodeling LV volumes and dimensions LV ejection fraction Mitral regurgitation Reduction in heart failure (CRT) and allcause morbidity and mortality (CRT-D) Abraham WT, 23
16 CRT IMPROVES CARDIAC FUNCTION AT DIMINISHED ENERGY COST.24 MVO 2 / hr (relative units) p <.5 Dobutamine dp / dt max (mmhg/s) Nelson et Circulation 2;12: LV pacing NE Level pg/ml NE Levels: CRT a positive impact on NE levels Baseline Paced 12 wk N = 71 N = 15 P = NS N = 35 P = NS < > 8 Norepinephrine levels Saxon et al. PACE. 1999;22:4(pt II):83. Abstract 519. N = 21 P =.1 % improving 1 NYHA class > NYHA FUNCTIONAL CLASS 1 yr p <.1 PATH- CHF 1 yr p <.5 6 mo p <.5 6 mo p <.3 MUSTIC MIRACLE CONTAK CD (advanced HF)
17 74 mm Path CHF ECHO LVEDD Echo data (LVEDD) MUSTIC SR 7 NS 68 MUSTIC AF MIRACLE Pre-CRT CRT CONTAK CD Improvement (ml / kg / min) mo p =.3 PATH- CHF PEAK VO 2 No CRT 3 mo p =.3 6 mo p =.6 CRT 6 mo p =.4 MUSTIC MIRACLE CONTAK CD (advanced HF) Mean improvement in peak VO 2 ~ 2 ml / kg / min Improvement (meters) MINUTE WALK PATH- CHF No CRT 3 mo 3 mo p =.1 6 mo p =.3 CRT 6 mo p =.2 MUSTIC MIRACLE CONTAK CD (advanced HF) Mean improvement in meters walked ~ 6+ meters
18 Improvment QOL score (points) mo p =.3 PATH- CHF QUALITY OF LIFE No CRT 3 mo p <.1 CRT 6 mo p =.2 6 mo p =.2 MUSTIC MIRACLE CONTAK CD (advanced HF) Mean improvement ~ 17 points HF HOSPITALIZATION AMONG PTS RANDOMIZED TO CARDIAC RESYNCHRONIZATION vs NO RESYNCHRONIZATION Favors CR Favors No CR Contak CD OR.79 InSync ICD.81 Miracle.48 Total Odds ratio (95% Cl) *Meta-analysis of RCT Miracle (N = 263), Contak CD (N = 245), InSync ICD (N = 272) Bradley et al JAMA CARDIAC RESYNCHRONIZATION AND HOSPITALIZATION RISK Hospital admissions per patient 2 1 Cardiac 1. Anand et al JACC 29; 119:964 N = 152 p-value vs OPT OPT CRT-P p <.1 CRT-D p <.1 HF Time post randomization (mos).5
19 CRT AND ATRIAL FIBRILLATION Meta-Analysis of observational studies: 5 studies, total of 1164 subjects with CRT Findings (comparing CRT subjects with AF vs NSR): Similar NYHA class improvements after CRT Mortality not statistically different RR 1.57; 95% Cl, NSR: Greater improvements with 6- min walk and QOL AF: slightly greater improvement in LVEF Upadhyay GA et al, JACC 28;52: APPROPRIATE CANDIDATES FOR CRT BASED ON RANDOMIZED CLINICAL TRIALS: 28 Symptomatic heart failure despite stable, optimal medical therapy Moderate to severe heart failure (NYHA Class III/IV) LV ejection fraction 4% QRS 12 ms (intrinsic or paced) REVERSE TRIAL: Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction Patients: N=61, EF 4%, QRS d 12 ms, NYHA I and II, LVEDD 55 nn CRT on ± ICD 419 off 191 1º Endpoint: Composite HF morbidity, mortality; 1 st hospitalization, QOL Results: (1 year) Worse (disease progression surrogate): on 16%, off 21% (p=.1) LVEDV: on 18.4%, off 1.3 ml/m 2 (p <.1) Longer time to 1 st HF hospitalization (53% relative reduction) Linde et al JACC 28;52:1834 Multicenter
20 % CRT IN MILD HF (CLASS I, II) Clinical Composite at 1 yr % 16% 79% 84% CRT-OFF CRT-ON Worsened Improved/ unchanged CRT-off CRT-on CRT IN MILD HF (CLASS I, II LVESVI (ml/m 2 ) P < LVEDVI (ml/m 2 ) P < Base 12 Mo Base 12 Mo Base 12 Mo LVEF (ml/m 2 ) P <.1 % Patients Hospitalized for HF CRT IN MILD HF (CLASS I, II) Hazard ratio =.47 P =.3 CRT-OFF CRT-ON Months since randomization No. at risk CRT-OFF CRT-ON Linde et al JACC 28; 52:1834 N - 61 CRT on/off Linde et al JACC 28; 52:1834 N - 61 CRT on/off Linde et al JACC 28; 52:1834 N - 61 CRT on/off
21 MADIT-CRT (24-29) Primary Hypothesis: in minimally symptomatic cardiac pts. (NYHA I/II) with ischemic or nonischemic cardiomyopathy, decreased EF, and wide QRS, CRT-D will reduce mortality or HF event (which ever comes first) when compared to ICD-only therapy. It was anticipated in this prevention trial that there would be a low annual mortality rate in both Rx groups, with CRT-D benefit dominated by reduction in HF events.. MADIT-CRT Eligibility IHD NYHA class I or II NIHD NYHA class II EF <.3 QRS >13ms Meet AHA/ACC guideline indications for ICD Receiving optimal medical therapy Exclusion CABG, PCI, MI, NYHA III/IV within 3 months - AF within 1 month - Existing indication for CRT Having an implanted pacemaker, ICD, or CRT MADIT-CRT: PRIMARY END POINT First Occurrence 1. All-cause Mortality or 2. Heart-failure Event:* S & S or HF with response to RX involving a) IV decongestive therapy in an outpatient setting or b) augmented decongestive IV or oral therapy during in-hospital stay * Adjudicated by Independent Blinded End Point Review Committees
22 MADIT-CRT: Kaplan-Meier Estimate of Heart-failure Free Survival Probability N = 182 Hazard Ratio =.66 P<.1 Average FU = 2.4 yrs. MADIT-CRT: COX ANALYSES End Point Hazard ICD CRT Ratio P-Value 1 Analysis Death/HF.66.1 (n=182) 25.3% 17.2% Heart Failure 22.8% 13.9%.59 <.1 Death (any time) % 6.8% (mortality <3% per year) Variable Age <65 yr >65 yr Sex* Male Female NYHA Class Ischemic I Ischemia II Nonischemic II QRS ms* <15 >15 LVEF <.25 >.25 LVEDV <24ml >24ml LVESV <17 >17 All patients CRT-D:ICD Hazard Ratios for Prespecified Subgroups Hazard Ratio Significant Sex-Rx Interaction Significant QRS-Rx Interaction CRT-D Better ICD-only Better
23 Mean Changes in Echo LV Volumes and EF from Baseline to 1-year by Treatment Group ml P<.1 P<.1 = -37ml ml = -39ml EF = ml vs. 52 ml in LVEDV from baseline ml vs. 57ml in LVESV from baseline LVEDV LVESV LVEF N=62 N=746 ICD-only P<.1 CRT-D.3 vs..11 in LVEF from baseline CRT-D associated with significant reduction in heart size and improvement in heart function. MADIT-CRT: SUMMARY CRT-D: 34% reduction in death or HF in minimally symptomatic patients with ischemic or non-ischemic cardiomyopathy ( EF and QRS) CRT-D benefit: driven by improvement in LV function with 41% reduction in HF events CRT-D: more effective in women than men, and in patients with wider than narrower QRS complexes
The Role of ICD Therapy in Cardiac Resynchronization
The Role of ICD Therapy in Cardiac Resynchronization The Korean Society of Circulation 15 April 2005 Angel R. León, MD Carlyle Fraser Heart Center Division of Cardiology Emory University School of Medicine
More informationDo All Patients With An ICD Indication Need A BiV Pacing Device?
Do All Patients With An ICD Indication Need A BiV Pacing Device? Muhammad A. Hammouda, MD Electrophysiology Laboratory Department of Critical Care Medicine Cairo University Etiology and Pathophysiology
More informationArthur J. Moss, MD Professor of Medicine/Cardiology University of Rochester Medical Center Rochester, NY. DISCLOSURE INFORMATION Arthur J.
Saving Lives and Preventing Heart Failure: The MADIT Family of Trials Arthur J. Moss, MD Professor of Medicine/Cardiology University of Rochester Medical Center Rochester, NY Update in Electrocardiography
More informationPrimary prevention of SCD with the ICD in Nonischemic Cardiomyopathy
Primary prevention of SCD with the ICD in Nonischemic Cardiomyopathy Michael R Gold, MD, PhD Medical University of South Carolina Charleston, SC USA Disclosures: Consulting and Clinical Trials Medtronic
More informationRisk Stratification of Sudden Cardiac Death
Risk Stratification of Sudden Cardiac Death Michael R Gold, MD, PhD Medical University of South Carolina Charleston, SC USA Disclosures: None Sudden Cardiac Death A Major Public Health Problem > 1/2 of
More informationCardiac Devices CRT,ICD: Who is and is not a Candidate? Who Decides
Cardiac Devices CRT,ICD: Who is and is not a Candidate? Who Decides Colette Seifer MB(Hons) FRCP(UK) Associate Professor, University of Manitoba, Cardiologist, Cardiac Sciences Program, St Boniface Hospital
More informationDevices and Other Non- Pharmacologic Therapy in CHF. Angel R. Leon, MD FACC Division of Cardiology Emory University School of Medicine
Devices and Other Non- Pharmacologic Therapy in CHF Angel R. Leon, MD FACC Division of Cardiology Emory University School of Medicine Disclosure None University of Miami vs. OSU Renegade Miami football
More informationHeart failure and sudden death
Heart failure and sudden death What did we learn so far from important ICD- and CRT trials? Helmut U. Klein M.D. University of Rochester Medical Center Heart Research Follow up Program Arrhythmic substrate
More informationICD Therapy. Disclaimers
ICD Therapy Rodney Horton, MD Texas Cardiac Arrhythmia Institute Texas Cardiovascular, PA Austin, TX Speaker s Bureau St. Jude Medical Medtronic Boston Scientific Disclaimers Clinical Advisory Panel St.
More informationHF and CRT: CRT-P versus CRT-D
HF and CRT: CRT-P versus CRT-D Andrew E. Epstein, MD Professor of Medicine, Cardiovascular Division University of Pennsylvania Chief, Cardiology Section Philadelphia VA Medical Center Philadelphia, PA
More informationMADIT Studies: CRT in the Non-LBBB Patient and Other Findings. Arthur J. Moss, MD
MADIT Studies: CRT in the Non-LBBB Patient and Other Findings Arthur J. Moss, MD University of Rochester Medical Cntr. Rochester, NY 13 th Annual New Frontiers in Heart Failure Rx NYC, NY January 26, 2013
More informationCardiac Resynchronization ICD Therapy: What is New?
Cardiac Resynchronization ICD Therapy: What is New? Emile Daoud, MD Section Chief, Cardiac Electrophysiology Professor of Medicine The Ohio State University Normal Activation, Narrow QRS Synchrony Abnormal
More informationImplantable Cardioverter Defibrillator Therapy in MADIT II Patients with Signs and Symptoms of Heart Failure
Implantable Cardioverter Defibrillator Therapy in MADIT II Patients with Signs and Symptoms of Heart Failure Wojciech Zareba Postinfarction patients with left ventricular dysfunction are at increased risk
More informationBi-Ventricular pacing after the most recent studies
Seminars of the Hellenic Working Groups February 18th-20 20,, 2010, Thessaloniki, Greece Bi-Ventricular pacing after the most recent studies Maurizio Lunati MD Director EP Lab & Unit Cardiology Dpt. Niguarda
More informationSudden death as co-morbidity in patients following vascular intervention
Sudden death as co-morbidity in patients following vascular intervention Impact of ICD therapy Seah Nisam Director, Medical Science, Guidant Corporation Advanced Angioplasty Meeting (BCIS) London, 16 Jan,
More informationAll in the Past? Win K. Shen, MD Mayo Clinic Arizona Controversies and Advances in CV Diseases Cedars-Sinai Heart Institute, MFMER
ICD for NICM All in the Past? Win K. Shen, MD Mayo Clinic Arizona Controversies and Advances in CV Diseases Cedars-Sinai Heart Institute, 2017 2017 MFMER 3686275-1 DISCLOSURE Relevant Financial Relationship(s)
More informationImplantable cardioverter-defibrillators and cardiac resynchronization therapy
Implantable cardioverter-defibrillators and cardiac resynchronization therapy Johannes Holzmeister, MD University Hospital Zurich, Zurich, Switzerland Frontiers of heart failure controversies, ESC - Paris
More informationCardiac Resynchronization Therapy. Michelle Khoo, MD
Cardiac Resynchronization Therapy Michelle Khoo, MD 10.7.08 HuiKuri HV NEJM 2001 Sudden Death (SD) in Subset Populations HuiKuri HV NEJM 2001 Sudden Death (SD) in Subset Populations SD in Competitive Athletes
More informationTHE ROLE OF ICD THERAPY FOR PRIMARY PREVENTION Leonard Ganz, M.D. Pittsburgh, PA
THE ROLE OF ICD THERAPY FOR PRIMARY PREVENTION Leonard Ganz, M.D. Pittsburgh, PA Speakers Bureau: Zoll / Lifecore, Sanofi Aventis, Cardionet Consultant: Boston Scientific, St. Jude Medical, Biotronik,
More informationTachycardia Devices Indications and Basic Trouble Shooting
Tachycardia Devices Indications and Basic Trouble Shooting Peter A. Brady, MD., FRCP Cardiology Review Course London, March 6 th, 2014 2011 MFMER 3134946-1 Tachycardia Devices ICD Indications Primary and
More informationDialysis-Dependent Cardiomyopathy Patients Demonstrate Poor Survival Despite Reverse Remodeling With Cardiac Resynchronization Therapy
Dialysis-Dependent Cardiomyopathy Patients Demonstrate Poor Survival Despite Reverse Remodeling With Cardiac Resynchronization Therapy Evan Adelstein, MD, FHRS John Gorcsan III, MD Samir Saba, MD, FHRS
More informationComparison of clinical trials evaluating cardiac resynchronization therapy in mild to moderate heart failure
HOT TOPIC Cardiology Journal 2010, Vol. 17, No. 6, pp. 543 548 Copyright 2010 Via Medica ISSN 1897 5593 Comparison of clinical trials evaluating cardiac resynchronization therapy in mild to moderate heart
More informationPreventing Sudden Death Current & Future Role of ICD Therapy
Preventing Sudden Death Current & Future Role of ICD Therapy Derek V Exner, MD, MPH, FRCPC, FACC, FAHA, FHRS Professor, Libin Cardiovascular Institute of Alberta Canada Research Chair, Cardiovascular Clinical
More informationEffect of Ventricular Pacing on Myocardial Function. Inha University Hospital Sung-Hee Shin
Effect of Ventricular Pacing on Myocardial Function Inha University Hospital Sung-Hee Shin Contents 1. The effect of right ventricular apical pacing 2. Strategies for physiologically optimal ventricular
More informationWho does not need a primary preventive ICD?
Who does not need a primary preventive ICD? Hildegard Tanner, Bern Universitätsklinik für Kardiologie Disclosure of potential conflicts of interest Travel grants for educational purposes from: Biosense
More informationICD. Guidelines and Critical Review of Trials. Win K. Shen, MD Professor of Medicine Mayo Clinic College of Medicine Mayo Clinic Arizona Torino 2011
ICD Guidelines and Critical Review of Trials Win K. Shen, MD Professor of Medicine Mayo Clinic College of Medicine Mayo Clinic Arizona Torino 2011 Disclosure Relevant Financial Relationship(s) None Off
More informationHow do I convert my CRT Non Responder into Responder?
How do I convert my CRT Non Responder into Responder? Michael R Gold, MD, PhD Medical University of South Carolina Charleston, SC Disclosures: Clinical Trials and Consulting Boston Scientific, Medtronic
More informationCardiac Resynchronization Therapy Guidelines and Missing Groups
Cardiac Resynchronization Therapy Guidelines and Missing Groups Frank Pelosi, Jr., MD, FACC, FHRS Director, Cardiac Electrophysiology Fellowship Associate Professor of Medicine University of Michigan Health
More informationDevice Based Therapy for the Failing Heart: ICD and Cardiac Resynchronization Rx
Device Based Therapy for the Failing Heart: ICD and Cardiac Resynchronization Rx Charles Gottlieb, MD Director of Electrophysiology Abington Memorial Hospital Heart Failure Mortality Mechanism of death
More informationCRT-D or CRT-P: HOW TO CHOOSE THE RIGHT PATIENT?
CRT-D or CRT-P: HOW TO CHOOSE THE RIGHT PATIENT? Alessandro Lipari, MD Chair and Department of Cardiology University of Study and Spedali Civili Brescia -Italy The birth of CRT in Europe, 20 years ago
More informationImplantation of a CRT-Pacemaker Rather than CRT-Defibrillator is Usually Preferred
Implantation of a CRT-Pacemaker Rather than CRT-Defibrillator is Usually Preferred Professor John GF Cleland University of Hull Kingston-upon-Hull United Kingdom Conflict of Interest: Funding or Speakers
More informationPolypharmacy - arrhythmic risks in patients with heart failure
Influencing sudden cardiac death by pharmacotherapy Polypharmacy - arrhythmic risks in patients with heart failure Professor Dan Atar Head, Dept. of Cardiology Oslo University Hospital Ullevål Norway 27.8.2012
More informationIndications for and Prediction of Successful Responses of CRT for Patients with Heart Failure
Indications for and Prediction of Successful Responses of CRT for Patients with Heart Failure Edmund Keung, MD Clinical Chief, Cardiology Section San Francisco VAMC October 25, 2008 Presentation Outline
More informationSudden Cardiac Death and Asians Disclosures
Sudden Cardiac Death and Asians Disclosures 7 February 2009 Asian Heart and Vascular Symposium None Zian H. Tseng, M.D., M.A.S. Assistant Professor of Medicine Cardiac Electrophysiology Section University
More informationArrhythmias Focused Review. Who Needs An ICD?
Who Needs An ICD? Cesar Alberte, MD, Douglas P. Zipes, MD, Krannert Institute of Cardiology, Indiana University School of Medicine, Indianapolis, IN Sudden cardiac arrest is one of the most common causes
More informationDipartimento di Scienze Cardiovascolari Università Campus Bio-Medico di Roma Dott. Vito Calabrese
Dipartimento di Scienze Cardiovascolari Università Campus Bio-Medico di Roma Dott. Vito Calabrese Because the primary objective was cure symptomatic bradicardya due to syncope Because this is the common
More informationThoranis Chantrarat MD
Device Therapy in Heart Failure Thoranis Chantrarat MD 1 Scope of presentation Natural history of heart failure Primary and secondary prevention ICD and its indication CRT and its indication 2 Severity
More informationMichel Mirowski and colleagues ABSTRACT CARDIOLOGY. ICD Update: New Evidence and Emerging Clinical Roles in Primary Prevention of Sudden Cardiac Death
ICD Update: New Evidence and Emerging Clinical Roles in Primary Prevention of Sudden Cardiac Death Ronald D. Berger, MD, PhD, FACC ABSTRACT PURPOSE: To review recent major randomized trials of implantable
More informationShock Reduction Strategies Michael Geist E. Wolfson MC
Shock Reduction Strategies Michael Geist E. Wolfson MC Shock Therapy Thanks, I needed that! Why Do We Need To Reduce Shocks Long-term outcome after ICD and CRT implantation and influence of remote device
More informationBENEFIT OF CRT IN MILDLY SYMPTOMATIC HEART FAILURE RECENT DATA FROM MADIT-CRT AND RAFT
BENEFIT OF CRT IN MILDLY SYMPTOMATIC HEART FAILURE RECENT DATA FROM MADIT-CRT AND RAFT Ilan Goldenberg MD Professor of Cardiology Sheba Medical Center and Tel Aviv University, Israel University of Rochester
More informationThe Role of ACEI and ARBs in AF prevention
The Role of ACEI and ARBs in AF prevention Dr. Sameh Shaheen MD, FESC Prof. of cardiology Ain-Shams university Time course of atrial substrate remodeling in relation to the clinical appearance of AF and
More informationICD Guidelines: who benefits from an ICD?
ICD Guidelines: who benefits from an ICD? Matthew Bennett Cardiac Electrophysiologist Vancouver Coastal Health, Device Lead Associate Professor, UBC Matthew.bennett@vch.ca Disclosures I have research collaborations
More informationAtrial Fibrillation Ablation in Patients with Heart Failure
Atrial Fibrillation Ablation in Patients with Heart Failure Eleftherios M. Kallergis, MD, PhD, FESC Cardiology Department, Heraklion University Hospital Since auricular fibrillation so often complicates
More informationDevice based CRT optimization: is there a future? Lessons learned from published trials
Device based CRT optimization: is there a future? Lessons learned from published trials C. Leclercq Department of Cardiology Centre Cardio-Pneumologique Rennes, France Presenter Disclosure Information
More informationDevice Therapy for Heart Failure
Device Therapy for Heart Failure Dr. Shelley Zieroth FRCPC Assistant Professor, Cardiology, University of Manitoba Director of Cardiac Transplant and Heart Failure Clinics St Boniface General Hospital,
More informationLarge RCT s of CRT 2002 to present
Have We Expanded Our Use of CRT for Heart Failure Patients? Sana M. Al-Khatib, MD, MHS Associate Professor of Medicine Electrophysiology Section- Division of Cardiology Duke University Potential Conflicts
More informationThe Role of Ventricular Electrical Delay to Predict Left Ventricular Remodeling With Cardiac Resynchronization Therapy
The Role of Ventricular Electrical Delay to Predict Left Ventricular Remodeling With Cardiac Resynchronization Therapy Results from the SMART-AV Trial Michael R. Gold, MD, PhD, Ulrika Birgersdotter-Green,
More informationIndications for ICD Therapy and Their Safety
Indications for ICD Therapy and Their Safety Blair W. Foreman, MD, FACC Cardiovascular Medicine, P.C. October 11, 2008 This slide set was adapted from the ACC/AHA/HRS 2008 Guidelines for Device Based Therapy
More informationEndpoints When Treating VT/VF in Patients with ICDs Programming Wojciech Zareba, MD, PhD
Endpoints When Treating VT/VF in Patients with ICDs Programming Wojciech Zareba, MD, PhD Professor of Cardiology/Medicine Director of the Heart Research Follow Up Program, University of Rochester, Rochester,
More informationRole of Non-Implantable Defibrillators in the Management of Patients at High Risk for Sudden Cardiac Death
Role of Non-Implantable Defibrillators in the Management of Patients at High Risk for Sudden Cardiac Death 29 October 2011 Update in Electrocardiography and Arrhythmias Zian H. Tseng, M.D., M.A.S. Associate
More informationUnderstanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials -
Understanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials - Clinical trials Evidence-based medicine, clinical practice Impact upon Understanding pathophysiology
More informationEffects of heart rate reduction with ivabradine on left ventricular remodeling and function:
Systolic Heart failure treatment with the If inhibitor ivabradine Trial Effects of heart rate reduction with ivabradine on left ventricular remodeling and function: results of the SHIFT echocardiography
More informationHeart Failure Overview. Dr Chris K Y Wong
Heart Failure Overview Dr Chris K Y Wong Heart Failure: A Growing, Global Health Issue Heart Failure 23 Million Afflicted Global Impact Worldwide ~23 million peopleworldwide afflicted with CHF 1 Exceeds
More informationESC Stockholm Arrhythmias & pacing
ESC Stockholm 2010 Take Home Messages for Practitioners Arrhythmias & pacing Prof. Panos E. Vardas Professor of Cardiology Heraklion University Hospital Crete, Greece Disclosures Small teaching fees from
More informationHeart Failure Management. Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist
Heart Failure Management Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist Heart failure prevalence is expected to continue to increase¹ 21 MILLION ADULTS WORLDWIDE
More informationCRT-P or CRT-D From North Alberta to Nairobi
CRT-P or CRT-D From North Alberta to Nairobi Dr Mzee Ngunga Aga Khan University Hospital Nairobi KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web:
More informationCardiac resynchronization therapy for heart failure: state of the art
Cardiac resynchronization therapy for heart failure: state of the art Béla Merkely MD, PhD, DSc, FESC, FACC Vice president of the European Society of Cardiology Honorary president of the Hungarian Society
More informationSUDDEN CARDIAC DEATH(SCD): Definition
SUDDEN CARDIAC DEATH EPIDEMIOLOGY, PATHOPHYSIOLOGY, PREVENTION & THERAPY Hasan Garan, M.D. Columbia University Medical Center SUDDEN CARDIAC DEATH(SCD): Definition DEATH DUE TO A CARDIAC CAUSE IN A CLINICALLY
More informationAntiarrhythmic Drugs and Ablation in Patients with ICD and Shocks
Antiarrhythmic Drugs and Ablation in Patients with ICD and Shocks Alireza Ghorbani Sharif, MD Interventional Electrophysiologist Tehran Arrhythmia Clinic January 2016 Recurrent ICD shocks are associated
More informationLa gestione di un paziente con ICD: come evitare gli shock inappropriati e prolungare la sopravvivenza del paziente. Maurizio Gasparini
La gestione di un paziente con ICD: come evitare gli shock inappropriati e prolungare la sopravvivenza del paziente Maurizio Gasparini Responsabile UO Elettrofisiologia ed Elettrostimolazione Humanitas
More informationProvocative Cases: Issues in the Expanding Use of CRT in Treating CHF Patients
Provocative Cases: Issues in the Expanding Use of CRT in Treating CHF Patients David E. Krummen, MD Associate Professor of Medicine University of California San Diego and VA San Diego Healthcare System
More informationResynchronization/Defibrillation
Resynchronization/Defibrillation for Ambulatory Heart Failure Trial Cardiac Resynchronization Therapy for Mild to Moderate Heart Failure George Wells University of Ottawa Heart Institute Department of
More informationSUDDEN CARDIAC DEATH(SCD): Definition
SUDDEN CARDIAC DEATH EPIDEMIOLOGY, PATHOPHYSIOLOGY, PREVENTION & THERAPY Hasan Garan, M.D. Columbia University Medical Center SUDDEN CARDIAC DEATH(SCD): Definition DEATH DUE TO A CARDIAC CAUSE IN A CLINICALLY
More informationSudden Cardiac Death What an electrophysiologist thinks a cardiologist should know
Sudden Cardiac Death What an electrophysiologist thinks a cardiologist should know Steven J. Kalbfleisch, M.D. Medical Director Electrophysiology Laboratory Ross Heart Hospital Wexner Medical Center Sudden
More informationJean François Leclercq Department of Rythmology Private Hospital of Parly 2 - Le Chesnay F
SECONDARY PREVENTION of Sudden Death: in which patients? Jean François Leclercq Department of Rythmology Private Hospital of Parly 2 - Le Chesnay F Why an AID is effective? Because it stoppes a VT very
More informationRole of Ablation of AF and PVCs in the Management of Heart Failure
Role of Ablation of AF and PVCs in the Management of Heart Failure Cara Pellegrini, MD, FHRS Acting Chief, Cardiology, SF VA Associate Professor of Medicine, UCSF Disclosures I have nothing to disclose
More information8/8/2011. CARDIAC RESYCHRONIZATION THERAPY for Heart Failure. Case Presentation. Case Presentation
CARDIAC RESYCHRONIZATION THERAPY for Heart Failure James Taylor, DO, FACOS Cardiothoracic and Vascular surgery San Angelo Community Medical Center San Angelo, TX Case Presentation 64 year old female with
More informationVentricular Tachycardia Ablation. Saverio Iacopino, MD, FACC, FESC
Ventricular Tachycardia Ablation Saverio Iacopino, MD, FACC, FESC ü Ventricular arrhythmias, both symptomatic and asymptomatic, are common, but syncope and SCD are infrequent initial manifestations of
More informationWhat Every Physician Should Know:
What Every Physician Should Know: The Canadian Heart Rhythm Society estimates that, in Canada, sudden cardiac death (SCD) is responsible for about 40,000 deaths annually; more than AIDS, breast cancer
More informationThe Management of Heart Failure after Biventricular Pacing
The Management of Heart Failure after Biventricular Pacing Juan M. Aranda, Jr., MD University of Florida College of Medicine, Division of Cardiovascular Medicine, Gainesville, Florida Approximately 271,000
More informationDefibrillation threshold testing should no longer be performed: contra
Defibrillation threshold testing should no longer be performed: contra Andreas Goette St. Vincenz-Hospital Paderborn Dept. of Cardiology and Intensive Care Medicine Germany No conflict of interest to disclose
More informationAtrial Fibrillation and Heart Failure
Date Clinical Title Atrial Fibrillation and Heart Failure Raul Weiss MD, FAHA, FACC, FHRS and CCDS Director, Electrophysiology Fellowship Program Professor of Medicine The Ohio State University Wexner
More informationCT Academy of Family Physicians Scientific Symposium October 2012 Amit Pursnani, MD
CT Academy of Family Physicians Scientific Symposium October 2012 Amit Pursnani, MD Clinical syndrome resulting from a structural or functional cardiac disorder that impairs the ability of the heart to
More informationCardiac Resynchronization Therapy for Heart Failure
Cardiac Resynchronization Therapy for Heart Failure Ventricular Dyssynchrony vs Resynchronization Ventricular Dysynchrony Ventricular Dysynchrony 1 Electrical: Inter- or Intraventricular conduction delays
More informationRecurrent Implantable Defibrillator Discharges (ICD) Discharges ICD Storm
Recurrent Implantable Defibrillator Discharges (ICD) Discharges ICD Storm Guy Amit, MD, MPH Soroka University Medical Center Ben-Gurion University of the Negev Beer-Sheva, Israel Disclosures Consultant:
More informationLa stimulation biventriculaire (Traitement par Resynchronisation Cardiaque) Indications et Résultats. Daniel Gras, DIU, Paris 2007
La stimulation biventriculaire (Traitement par Resynchronisation Cardiaque) Indications et Résultats, DIU, Paris 2007 CRT: Results and indications Background Results of CRT Studies Today s classical CRT
More informationThis is What I do to Improve CRT Response for CRT Non-Responders
This is What I do to Improve CRT Response for CRT Non-Responders Michael R Gold, MD, PhD Medical University of South Carolina Charleston, SC Disclosures: Steering Committees (unpaid) and Clinical Trials,
More informationDevice detected VT: How much VT is significant and is VT ablation the answer?
Device detected VT: How much VT is significant and is VT ablation the answer? Dr Mark Mason Harefield Hospital Royal Brompton and Harefield NHS Foundation Trust What is VT (in this context)? What is VT?
More informationVentricular tachycardia and ischemia. Martin Jan Schalij Department of Cardiology Leiden University Medical Center
Ventricular tachycardia and ischemia Martin Jan Schalij Department of Cardiology Leiden University Medical Center Disclosure: Research grants from: Boston Scientific Medtronic Biotronik Sudden Cardiac
More informationSynopsis of Management on Ventricular arrhythmias. M. Soni MD Interventional Cardiologist
Synopsis of Management on Ventricular arrhythmias M. Soni MD Interventional Cardiologist No financial disclosure Premature Ventricular Contraction (PVC) Ventricular Bigeminy Ventricular Trigeminy Multifocal
More informationResponse of Right Ventricular Size to Treatment with Cardiac Resynchronization Therapy and the Risk of Ventricular Tachyarrhythmias in MADIT-CRT
Response of Right Ventricular Size to Treatment with Cardiac Resynchronization Therapy and the Risk of Ventricular Tachyarrhythmias in MADIT-CRT Heart Rhythm Society (May 11, 2012) Colin L. Doyle, BA,*
More informationTreatment of Atrial Fibrillation in Heart Failure
Stockholm, September 1st 2010 Treatment of Atrial Fibrillation in Heart Failure Rhythm control: Which drugs? Stefan H. Hohnloser J.W. Goethe University Frankfurt, Germany Presenter disclosure information:
More informationInteresting EP Cases Catheter ablation to treat congestive heart failure (CHF)
Interesting EP Cases Catheter ablation to treat congestive heart failure (CHF) Yiming WU, MD, PhD. Alaska heart and vascular institute. ywu@alaskaheart.com 907-561-3211 19 yo man transferred for out side
More information2017 AHA/ACC/HRS Ventricular Arrhythmias and Sudden Cardiac Death Guideline. Top Ten Messages. Eleftherios M Kallergis, MD, PhD, FESC
2017 AHA/ACC/HRS Ventricular Arrhythmias and Sudden Cardiac Death Guideline Top Ten Messages Eleftherios M Kallergis, MD, PhD, FESC Cadiology Department - Heraklion University Hospital No actual or potential
More informationLive Better Electrically
1 Live Better Electrically Steven L. Higgins, MD, FHRS Chairman, Dept. of Cardiology Director, Cardiac Electrophysiology Scripps Memorial Hospital, La Jolla San Diego, California 2 Live Better Electrically
More informationI NON RESPONDERS ALLA CRT: UN PROBLEMA DI NON SEMPLICE SOLUZIONE
I NON RESPONDERS ALLA CRT: UN PROBLEMA DI NON SEMPLICE SOLUZIONE Gaetano Senatore S.C. CARDIOLOGIA OSPEDALE DI CIRIE & OSPEDALE DI IVREA LABORATORIO di Today s Patient Selection for CRT +AF and PM patients
More informationImportance of CRT team for optimization of the results: a European point of view
Importance of CRT team for optimization of the results: a European point of view Matteo Bertini, MD, PhD Arcispedale S. Anna Azienda Ospedaliero-Universitaria Cona-Ferrara No conflict of interest to declare
More informationSilvia G Priori MD PhD
The approach to the cardiac arrest survivor Silvia G Priori MD PhD Molecular Cardiology, IRCCS Fondazione Salvatore Maugeri Pavia, Italy AND Leon Charney Division of Cardiology, Cardiovascular Genetics
More informationCRT: whom does it benefit?
CRT: whom does it benefit? Francisco Leyva BSH Revalidation and Training 2018 Queen Elizabeth Hospital NICE guidelines for CRT LVEF 35% NYHA class I II III IV QRS
More informationHeart Failure Medical and Surgical Treatment
Heart Failure Medical and Surgical Treatment Daniel S. Yip, M.D. Medical Director, Heart Failure and Transplantation Mayo Clinic Second Annual Lakeland Regional Health Cardiovascular Symposium February
More informationHeart Failure Treatments
Heart Failure Treatments Past & Present www.philippelefevre.com Background Background Chronic heart failure Drugs Mechanical Electrical Background Chronic heart failure Drugs Mechanical Electrical Sudden
More informationThe Hearth Rate modulators. How to optimise treatment
The Hearth Rate modulators How to optimise treatment Munich, ESC Congress 2012 Prof. Luigi Tavazzi GVM Care&Research E.S. Health Science Foundation Cotignola, IT Disclosure Cooperation with: Servier, Medtronic,
More informationTranscatheter Mitral Valve Repair and Replacement: Where is the Latest Randomized Evidence Taking US Mitral-Fr, COAPT
Transcatheter Mitral Valve Repair and Replacement: Where is the Latest Randomized Evidence Taking US Mitral-Fr, COAPT and Saibal Kar, MD, FACC, FSCAI Professor of Medicine Director of Interventional Cardiac
More informationBurden of Mitral Regurgitation (MR) in the US Why is This Important?
Secondary (Functional) Mitral Regurgitation as a Target for Heart Failure Therapy William T. Abraham, MD, FACP, FACC, FAHA, FESC, FRCP Professor of Medicine, Physiology, and Cell Biology Chair of Excellence
More informationJournal of the American College of Cardiology Vol. 61, No. 14, by the American College of Cardiology Foundation ISSN /$36.
Journal of the American College of Cardiology Vol. 61, No. 14, 2013 2013 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2013.01.020
More informationArrhythmias and Heart Failure Dr Chris Lang Consultant Cardiologist and Electrophysiologist Royal Infirmary of Edinburgh
Arrhythmias and Heart Failure Dr Chris Lang Consultant Cardiologist and Electrophysiologist Royal Infirmary of Edinburgh Arrhythmias and Heart Failure Ventricular Supraventricular VT/VF Primary prevention
More informationEffects of heart rate reduction with ivabradine on left ventricular remodeling and function:
Systolic Heart failure treatment with the If inhibitor ivabradine Trial Effects of heart rate reduction with ivabradine on left ventricular remodeling and function: results of the SHIFT echocardiography
More informationCardiac Resynchronisation Therapy for all Patients Requiring Ventricular Pacing
Cardiac Resynchronisation Therapy for all Patients Requiring Ventricular Pacing Philippe Mabo University Hospital, Rennes, France ESC Congress 2010, Stockholm 29 Aug 2010 Which Patients? Candidate for
More informationBiventricular Pacemakers (Cardiac Resynchronization Therapy) for the Treatment of Heart Failure
Last Review Status/Date: June 2015 Page: 1 of 29 Resynchronization Therapy) for the Treatment Description Cardiac resynchronization therapy (CRT), which consists of synchronized pacing of the left and
More informationContinuous ECG telemonitoring with implantable devices: the expected clinical benefits
Continuous ECG telemonitoring with implantable devices: the expected clinical benefits C. W. Israel, M.D. Dept. of Cardiology Evangelical Hospital Bielefeld Germany Carsten.Israel@evkb.de Declaration of
More information